Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL

Bart A. Nijmeijer, Marianke L. J. van Schie, Constantijn J. M. Halkes, Marieke Griffioen, Roelof Willemze, J. H. Frederik Falkenburg

Blood (2010) 116 (26): 5930–5940.

https://doi.org/10.1182/blood-2010-01-262006

Published: 2010

Journal Articles

Proliferation of Acute Lymphoblastic Leukemic (ALL) Cells Is Dependent on Exogenous Purine Administration.

Henriette M. Goselink, BS, Bart A. Nijmeijer, Cornelis H. Hokke, Rob van der Heijden, Roel Willemze, J.H. Frederik Falkenburg

Blood (2007) 110 (11): 3466.

https://doi.org/10.1182/blood.V110.11.3466.3466

Published: 2007

Journal Articles

The Prodrug AQ4N Displays Potent Anti-Tumor Activity in a Xenotransplantation Model of Primary Human Acute Lymphoblastic Leukemia.

Bart A. Nijmeijer, Marianke L.J. Van Schie, Susan E. Alters, Alvin Wong, Jeffrey L. Cleland, Roelof Willemze, J.H. Frederik Falkenburg

Blood (2005) 106 (11): 1837.

https://doi.org/10.1182/blood.V106.11.1837.1837

Published: 2005

Journal Articles

In Vitro Cell Division Analysis Reveals High Proliferative Potential and Clonogenicity within Primary Common-Type Human Acute Lymphoblastic Leukemia.

Bart A. Nijmeijer, Marianke L.J. Van Schie, Roelof Willemze, J.H. Frederik Falkenburg

Blood (2005) 106 (11): 857.

https://doi.org/10.1182/blood.V106.11.857.857

Published: 2005

Journal Articles

Toxicity and Effectivity of the Experimental Cytotoxic Drug Cyclopentenyl Cytosine in NOD/scid Mice with Acute Lymphoblastic Leukemia (ALL).

Kirsten J.M. Schimmel, PharmD, Bart A. Nijmeijer, PhD, Marianke L.J. van Schie, J.H. Frederik Falkenburg, PhD, Henk-Jan Guchelaar, PhD

Blood (2005) 106 (11): 4574.

https://doi.org/10.1182/blood.V106.11.4574.4574

Published: 2005

Journal Articles

Expansion and Transformation of Primary Acute Lymphoblastic Leukemia Cells into Antigen-Presenting Cells using a Novel Culturing System Enables the Generation of Leukemia-Reactive T Cell Responses that Are Effective in Vivo.

Bart A. Nijmeijer, Marianke L.J. Van Schie, Roel Willemze, J.H. Frederik Falkenburg

Blood (2004) 104 (11): 303.

https://doi.org/10.1182/blood.V104.11.303.303

Published: 2004

Journal Articles

An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/scid mice

Bart A. Nijmeijer, Roel Willemze, J. H. Frederik Falkenburg

Blood (2002) 100 (2): 654–660.

https://doi.org/10.1182/blood.V100.2.654

Published: 2002

NARROW

A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL

Proliferation of Acute Lymphoblastic Leukemic (ALL) Cells Is Dependent on Exogenous Purine Administration.

The Prodrug AQ4N Displays Potent Anti-Tumor Activity in a Xenotransplantation Model of Primary Human Acute Lymphoblastic Leukemia.

In Vitro Cell Division Analysis Reveals High Proliferative Potential and Clonogenicity within Primary Common-Type Human Acute Lymphoblastic Leukemia.

Toxicity and Effectivity of the Experimental Cytotoxic Drug Cyclopentenyl Cytosine in NOD/scid Mice with Acute Lymphoblastic Leukemia (ALL).

Expansion and Transformation of Primary Acute Lymphoblastic Leukemia Cells into Antigen-Presenting Cells using a Novel Culturing System Enables the Generation of Leukemia-Reactive T Cell Responses that Are Effective in Vivo.

An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/scid mice

Email alerts

ASH Publications

American Society of Hematology

A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL

Proliferation of Acute Lymphoblastic Leukemic (ALL) Cells Is Dependent on Exogenous Purine Administration.

The Prodrug AQ4N Displays Potent Anti-Tumor Activity in a Xenotransplantation Model of Primary Human Acute Lymphoblastic Leukemia.

In Vitro Cell Division Analysis Reveals High Proliferative Potential and Clonogenicity within Primary Common-Type Human Acute Lymphoblastic Leukemia.

Toxicity and Effectivity of the Experimental Cytotoxic Drug Cyclopentenyl Cytosine in NOD/scid Mice with Acute Lymphoblastic Leukemia (ALL).

Expansion and Transformation of Primary Acute Lymphoblastic Leukemia Cells into Antigen-Presenting Cells using a Novel Culturing System Enables the Generation of Leukemia-Reactive T Cell Responses that Are Effective in Vivo.

An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/scid mice

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only